Table 2. . CD73 blockade in the clinic.
| Tumor | Drug | Phase | Period | Sponsor | Identifier |
|---|---|---|---|---|---|
| Advanced solid tumors | MEDI9447 as monotherapy and in combination with MEDI4736 | Phase I | 2015–2021 | MedImmune LLC | NCT02503774 |
| Advanced solid tumors | BMS-986179 as monotherapy and in combination with nivolumab (BMS-936558) | Phase I/IIa | 2016–2020 | Bristol-Myers Squibb | NCT02754141 |
| NSCLC, RCC, PDAC, Ovarian cancer, MSS and TNBC | NZV930 as monotherapy and in combination with PDR001 and/or NIR178 | Phase I | 2018–2022 | Novartis Pharmaceuticals | NCT03549000 |
| NSCLC | MEDI9447 in combination with osimertinib or AZD4635 | Phase I Phase II |
2018–2021 | MedImmune LLC | NCT03381274 |
| Ovarian cancer | MEDI9447 in combination with durvalumab (anti-PD-L1), tremelilumab (anti-CTLA-4), and MEDI0562 (anti-OX40) | Phase II | 2018–2023 | Nordic Society for Gynaecologic Oncology | NCT03267589 |
| TNBC | MEDI9447 in combination with paclitaxel plus carboplatin and durvalumab | Phase I Phase II |
2018–2022 | Jules Bordet Institute | NCT03616886 |
| NSCLC, RCC, CRC, TNBC, cervical cancer, ovarian cancer, pancreatic cancer, endometrial cancer, sarcoma, HNSCC, bladder cancer and mCRPC | CPI-006 as monotherapy and in combination with CPI-444 or pembrolizumab | Phase I | 2018–2023 | Corvus Pharmaceuticals, Inc. | NCT03454451 |
CRC: Colorectal cancer; HNSCC: Squamous cell carcinoma of the head and neck; mCRPC: Metastatic castration-resistant prostate cancer; MSS: Colorectal cancer microsatellite stable; NSCLC: Non-small-cell lung cancer; PDAC: Pancreatic ductal adenocarcinoma; RCC: Renal cell cancer; TNBC: Triple-negative breast cancer.